Regenerative medicines are being given the green light in Japan with safety being the only hurdle. In light of this, there are significantly more new treatments being approved in Japan as compared to the US which has significantly higher requirements.
So although not direct competitors to MSBs product, the quantum of regenerative treatments , coupled with no real efficacy requirement, makes the market penetration significantly slower than what would be usually expected.
- Forums
- ASX - By Stock
- MSB
- Japan as a Funding Source
Japan as a Funding Source, page-4
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.25 |
Change
0.035(2.89%) |
Mkt cap ! $1.421B |
Open | High | Low | Value | Volume |
$1.21 | $1.25 | $1.18 | $4.096M | 3.347M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 22000 | $1.24 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.25 | 36989 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 22000 | 1.240 |
2 | 45159 | 1.235 |
4 | 42275 | 1.230 |
1 | 15746 | 1.225 |
5 | 56349 | 1.220 |
Price($) | Vol. | No. |
---|---|---|
1.245 | 36989 | 4 |
1.250 | 118007 | 15 |
1.255 | 236249 | 7 |
1.260 | 440345 | 9 |
1.265 | 67045 | 4 |
Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |